Prohemostatic proteins for the treatment of bleeding
AssigneeAcademisch Ziekenhuis Leiden
InventorsDaniël Verhoef, Pieter H. Reitsma, Mettine H. A. Bos
Life of this patent
Estimating the term…
Abstract
This disclosure relates to recombinant FXa polypeptides that can be used as antidotes to completely or partially reverse an anti-coagulant effect of a coagulation inhibitor in a subject, preferably a direct factor Xa inhibitor. Disclosed herein are recombinant factor Xa proteins and a method of completely or partially reversing an anti-coagulant effect of a coagulation inhibitor in a subject.
Claims13
A recombinant protein comprising a coagulation factor Xa polypeptide, said coagulation factor Xa polypeptide having an alteration or deletion of an amino acid residue corresponding to amino acid residue Phe-396 as indicated in SEQ ID NO:
- 1.
-6. (canceled)
-12. (canceled)
(canceled)
Dependencies are inferred from the claim text.